Prevention, treatment, and amelioration of radiation induced enteritis

Abstract

The present invention provides a new method of ameliorating and/or treating enteritis induced by radiation therapy, alone or in combination with other therapies, for the treatment of, for example, gastrointestinal malignancies, including colorectal, appendiceal, anal, or small bowel cancers; urogenital malignancies, including prostate, ladder, testicular, or penile cancers; gynecologic malignancies, including cervical, endometrial, ovarian, vaginal, or vulvar cancers; or osteogenic and other sarcomatous malignancies in which pelvic structures are involved, comprising the administration of a therapeutically effective amount of balsalazide to a patient in need thereof.

Description

[0001] Related applications [0002] This application claims priority to US Application Serial No. 10 / 856,348 filed May 28, 2004, which was converted to US Provisional Application Serial No. 60 / 608,951 on October 26, 2004. Both of the above are cited in their entirety in the disclosure content of this specification. technical field [0003] The present invention relates to the use of balsalazide to treat, prevent, or ameliorate enteritis. More specifically, the invention relates to the use of balsalazide, alone or in combination with other treatments, for the treatment of radiation induced enteritis resulting from radiation therapy. Background of the invention [0004] Various pelvic treatments (sometimes called "pelvic therapies)" including radiation therapy, chemotherapy, and surgery, in a variety of clinical situations, as, for example, neoplastic pelvic disorders Adjuvant or primary therapy in individuals with possible enterotoxicity and other side effects, such as acu...

AI Technical Summary

Problems solved by technology

[0005] The side effects of these various pelvic treatments cause discomfort and reduce the therapeutic benefit of the treatment by requiring unscheduled pauses in the treatment process

Images